Exscientia Business and Financial Update for the Third Quarter 2022
Exscientia plc (Nasdaq: EXAI)
Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the third quarter 2022, are summarised below. Exscientia will host a conference call today, November 15, at 1:30 p.m. GMT / 8:30 a.m. ET.
“At Exscientia, we are working towards the goal of leading the transformation of our industry’s approach to how drugs are created and how we can then specifically match these treatments to patients. Our capabilities in drug design and precision medicine have distinguished us as a pioneer in the field of AI-based drug discovery,” commented Professor Andrew Hopkins, D.Phil., Exscientia's founder and Chief Executive Officer. “Receiving the Prix Galien award in recognition of our integration of AI-driven precision medicine into drug discovery and development is a testament to our innovation. The concept of improving patient selection through our platform is a key tenet of our new strategic collaboration with The University of Texas MD Anderson Cancer Center, where we will combine our AI-driven drug discovery technology with the institution's deep clinical expertise in oncology to develop treatments for patients. We believe that this partnership, in addition to our recent expansion into biologics, further positions us as leaders in the field as we continue to advance our pipeline and enhance our end-to-end platform.”
Exscientia announced novel patient stratification methods and biomarker data supporting development of GTAEXS-617 ('617) at the 34th EORTC-NCI-AACR (ENA) Annual Symposium
- CTA submission expected by year-end 2022
- Anticipate Phase 1/2 study to begin in the first half of 2023 in multiple solid tumour indications, including ovarian cancer
The Company remains on track to initiate “IGNITE-AI,” a Phase 1b/2 study of its A2A programme EXS-21546 ('546) by year-end 2022
- Planned clinical study to look at combination therapies, including checkpoint inhibitors
New results outlining a predictive biomarker for patient selection, identified using Exscientia's precision medicine platform, will be shared on today’s call
- Additional data on patient selection modelling to be presented at a medical meeting by year-end 2022
Yesterday, Exscientia and MD Anderson, a premier cancer research and treatment centre in the United States, announced a strategic collaboration to develop small-molecule therapies in oncology
- The agreement aligns MD Anderson's drug development expertise with Exscientia's AI-based patient-first precision medicine and drug discovery platforms
- Additional target advanced in Sanofi collaboration for oncology
- Continued progress in Bristol Myers Squibb (BMS) collaboration with all programmes from the 2021 expansion currently in the design phase
Expansion into new modality with biologics AI design
- Exscientia announced the expansion of its platform for fast and accurate generative AI design of novel antibodies
- Produced accurate protein modelling up to 35,000 times faster than Alphafold2
- Approach of virtually modelling antibodies enables an evaluation of far more possibilities than laboratory screening, which Exscientia believes will help find the right antibody for a specific target
- Exscientia’s deep learning virtual screening methodology for antibodies is now over three times more accurate than the published state-of-the-art
- Sequencing paired human antibody data to create better AI models for antibody design
- An additional 8,000 square foot laboratory facility in Oxford Science Park will automate the production of proprietary data for each antibody, measuring essential qualities including affinity, immunogenicity, aggregation and stability
- The Company's precision medicine platform is uniquely positioned for the characterisation of biologics in the oncology space with proven preclinical data from development of monoclonal and bi-specific immunotherapies
Next-generation sequencing (NGS) integrated into precision medicine platform
- Exscientia's newly established NGS capabilities enable state-of-the-art bulk and single-cell sequencing technologies, which can now be used across all Exscientia programmes, regardless of phase
- The scalable sequencing platform allows time-efficient in-house genomic and transcriptomic profiling of all cancer patient tissue samples as well as the characterisation of the intratumoural heterogeneity, the tumour microenvironment and anti-tumour drug compound response at single-cell resolution
Exscientia recognition and leadership expansion
- Awarded the Prix Galien USA 2022 Digital Health Solution for Exscientia's AI-driven precision medicine platform. The Prix Galien recognises excellence in scientific innovation that improves the state of human health
- Exscientia was pleased to welcome Caroline Rowland to the Company's executive team as Chief People Officer in September. Caroline brings a wealth of deep tech experience in building culture and developing high performing teams
Investor call and webcast information
Exscientia will host a conference call today, November 15 at 1:30 p.m. GMT / 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialling +1 (888) 330 3292 (U.S.), +44 203 433 3846 (U.K.), +1 (646) 960 0857 (International) and entering the conference ID: 8333895. A replay will be available for 90 days under "Events and Presentations” in the “Investors and Media” section of the Exscientia website.
Third quarter and first nine months 2022 financial results
Exscientia consolidates and reports its financials in pounds sterling. For the convenience of the reader, the Company has translated pounds sterling amounts to U.S. dollars at the rate of £1.000 to $1.1134, which was the noon buying rate of the Federal Reserve Bank of New York on September 30, 2022.
Revenue: Recognised revenue for the three and nine months ended September 30, 2022, was $7.0 million and $22.7 million, respectively, compared to $19.6 million and $25.9 million for the three and nine months ended September 30, 2021.
Research and development expenses: R&D expenses for the three and nine months ended September 30, 2022, were $40.9 million and $103.8 million, respectively, as compared to $14.4 million and $28.2 million for the three and nine months ended September 30, 2021. The increase in research and development expenses was in part due to the growth of Exscientia's internal and co-owned portfolio, in addition to increased headcount and other costs associated with the Company's continued technology investments. Share-based compensation accounted for $8.1 million for the quarter ended September 30, 2022, as compared to $2.4 million for the same period ended September 30, 2021.
General and administrative expenses: G&A expenses for the three and nine months ended September 30, 2022, were $11.5 million, or 18.3% of total operating expenses, and $33.6, or 20.5% of total operating expenses respectively. For the third quarter 2022, G&A expenses increased by $1.9 million compared to the third quarter 2021, primarily associated with an increase in personnel costs. Share-based compensation accounted for $3.2 million for the quarter ended September 30, 2022, as compared to $1.4 million for the same period ended September 30, 2021.
Cash inflows: For the first nine months of 2022, Exscientia received $117.3 million in cash inflows from its collaborations as compared to $67.5 million during the first nine months of 2021.
Net operating cash flow and cash balance: For the first nine months ending September 30, 2022, net operating cash outflows were $15.0 million, in comparison to net operating cash inflows of $8.3 million in the nine months of 2021. Cash, cash equivalents and bank deposits as of September 30, 2022, were $624.7 million as compared to $625.9 million as of December 31, 2021.
- Includes constant currency mark-to-market foreign exchange impact of negative 9% based on the strength of the USD during the quarter
- During the quarter, Exscientia recognised realised foreign exchange gains of $8.3 million
- The Company holds its deposits in both GBP and USD intended to match expected operational cash needs in order to limit the impact of exchange rate fluctuations
SELECTED CONSOLIDATED STATEMENT OF OPERATIONS, CONSTANT CURRENCY CONVERSION (unaudited)
($ millions, except per share data, at the rate of £1.000 to $1.1134)
Three months ended
Nine months ended
Cost of sales
Research and development expenses
General and administrative expenses
Foreign exchange gains/(losses)
Loss on forward contracts
Share of loss on joint ventures
Loss on derivative financial instrument
Loss before taxation
Income tax benefit
Loss for the period
Net loss per share
SELECTED CONSOLIDATED BALANCE SHEET, CONSTANT CURRENCY CONVERSION (unaudited)
($ millions, except per share data, at the rate of £1.000 to $1.1134)
September 30, 2022
December 31, 2021
Cash, cash equivalents and short term bank deposits
Total equity and liabilities
SELECTED CONSOLIDATED STATEMENT OF CASH FLOWS, CONSTANT CURRENCY CONVERSION (unaudited)
($ millions, except per share data, at the rate of £1.000 to $1.1134)
Nine months ended September 30,
Net cash (outflows)/inflows from operating activities
Net cash flows used in investing activities*
Net cash (used in)/generated from financing activities
Net (decrease)/increase in cash and cash equivalents
Net (decrease)/increase in cash, cash equivalents and short-term bank deposits
* Includes the impact of $111.3 million that was transferred from cash accounts into short-term bank deposits
Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.
Exscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding the performance of its technology platforms or its projected revenue and cash runway. Any statement describing Exscientia’s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company’s business, including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https://www.sec.gov/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgement of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global donors pledge over US$777 million to defeat neglected tropical diseases and improve the lives of 1.6 billion people at the Reaching the Last Mile Forum at COP283.12.2023 15:40:00 CET | Press release
Global donors at the 2023 Reaching the Last Mile Forum today pledged a collective US$777.2 million to help control, eliminate, and eradicate neglected tropical diseases (NTDs), in a landmark push to accelerate progress towards achieving the goals outlined in the World Health Organization’s 2030 roadmap on NTDs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203773888/en/ Uniting efforts with NTD-endemic countries, donors answered the urgent call to step up the fight against NTDs in the face of climate change, and to work together to improve the lives of the 1.6 billion people worldwide affected by these devastating yet preventable diseases. The pledging event was hosted by Reaching the Last Mile (RLM), the global health initiative driven by the philanthropy of His Highness Sheikh Mohamed Bin Zayed Al Nahyan, President of the UAE, in partnership with the Bill & Melinda Gates Foundation. The forum took place on the first ev
Sharjah Celebrates the UAE’s 52nd Union Day3.12.2023 09:22:00 CET | Press release
Sharjah concluded the 52nd Union Day celebrations, which lasted for 12 days, with wide participation from all segments of society including government entities, private sector institutions, Emiratis, international residents, and visitors to the emirate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231203827502/en/ From the Union Day celebration in Sharjah (Photo 1: AETOSWire) Over 200 activities organized by the Sharjah National Day Celebrations Committee took place in the cities of Sharjah, Mleiha, Dibba Al Hosn, Khorfakkan, Kalba, Al Bataeh, Al Mudam, Al Dhaid, and Al Hamriyah. Celebrations also took place in cultural and tourist areas as Al Dhaid Fort, the heritage villages in Al Hamriyah, Mleiha, Kalba. Other locations included Wadi Al Hilo, the National Park in Sharjah, Al Hosn Island Canal, Khorfakkan Amphitheatre, Kalba Lake, and Al Bataeh Public Park. His Excellency Khalid Jasim Al Midfa, Chairman of the Sharjah Na
IFRC-DREF calls on global donors to help the world ‘Stand Tall’ in the face of accelerating humanitarian need - supporting smarter and faster disaster relief3.12.2023 01:01:00 CET | Press release
The International Federation of Red Cross and Red Crescent Societies (IFRC) has launched a new campaign to address rapidly escalating climate driven humanitarian crises. It calls on global governments and international donors to support local emergency responders and disaster hit communities - helping them to Stand Tall with smarter and faster humanitarian funding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231202510555/en/ Stand Tall in the face of disaster with IFRC-DREF Insurance. (Photo: Business Wire) The IFRC’s Disaster Response Emergency Fund (IFRC-DREF) is the quickest, most efficient and most transparent way of getting funding directly to local National Societies — both before and immediately after a crisis hits. Yet it faces growing pressure to anticipate and respond to multiple, simultaneous and complex crises around the world as a result of climate change. Today, 3.6 billion people live in areas highly suscep
11 Winners Recognised at Zayed Sustainability Prize Awards Ceremony held during COP28 UAE2.12.2023 03:15:00 CET | Press release
His Highness Sheikh Mohamed bin Zayed Al Nahyan, President of the UAE, today awarded the winners of the Zayed Sustainability Prize, the UAE’s pioneering global award in sustainability and humanitarianism, during a ceremony held at COP28 UAE in Expo City Dubai. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201649250/en/ 11 winners of the Zayed Sustainability Prize Recognised at COP28 (Photo: AETOSWire) The Ceremony was attended by numerous heads of delegations participating in COP28, ministers, senior government officials, and Prize winners and finalists. His Highness congratulated the winners, praising their efforts in promoting sustainability and encouraging them to continue their important contributions in this field. His Highness emphasised that the UAE is steadfast in building upon its established legacy in sustainability, a foundation laid by the country’s Founding Father, the late Sheikh Zayed bin Sultan Al Nahyan.
Zextras Introduces Carbonio - A Private Digital Workplace1.12.2023 16:07:00 CET | Press release
Zextras, the leading email and collaboration solutions provider, introduced Carbonio - a private digital workplace for the public sector and regulated industries. Carbonio emerges as an exceptional solution for the public sector, enabling them to implement an extensive digital workspace for their internal teams and stakeholders. Delivering a suite of features that are not only comprehensive but also fully customizable, from emails and calendars to video meetings and file storage, Carbonio allows for superior adaptation to any unique technical requirements or business objectives. It is equally enticing for regulated industries to enhance their operations by providing secure software solutions tailored to meet the distinct security needs of their country and respective states. The platform is rooted in robust compliance with global data protection regulations, including the European General Data Protection Regulation (GDPR). This fosters a secure digital environment for users, ensuring t